TB

Tuberculosis

\n
TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?
GLOBAL PLAN TO END TB, 2023-2030 – HOW FEASIBLE? HOW DESIRABLE?
Tuberculosis and Inequality: How Race, Caste, and Class Impact Access to Medicines
Johnson & Johnson’s Patenting & Pricing Strategy for TB Medicine Bedaquiline: A Cautionary Tale for New TB Medicines
How Advocates Pushed Big Pharma to Cut Tuberculosis Drug Prices
Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply
TB Preventive Treatment: the Need for Choice
Pharma Giant’s TB Drug Decision Welcomed, But Not All Developing Countries Benefit
MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics
Three Indian firms line up to make TB drug Bedaquiline as patent expires
Major drug company bends in battle over access to key TB treatment
Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign
Global Drug Facility Update on Access to Bedaquiline
TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
Gates Foundation to fund trial of long-awaited new tuberculosis vaccine candidate
Tuberculosis and Inequality: How Race, Caste, and Class Impact Access to Medicines
Subscribe to TB